MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
- Conditions
- Multiple Myeloma
- First Posted Date
- 2003-07-11
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT00063726
- Locations
- 🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸City of Hope, Duarte, California, United States
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- First Posted Date
- 2003-07-10
- Last Posted Date
- 2009-03-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00064584
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
- Conditions
- Multiple Myeloma
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2007-02-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00063791
- Locations
- 🇺🇸
Michael Meshad, Oncology Center, Mobile, Alabama, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Toledo Clinic, Toledo, Ohio, United States
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2003-07-04
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT00063713
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Alta Bates Medical Center, Berkeley, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-22
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT00051974
- Locations
- 🇺🇸
U of Alambama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center Thoracic Malignancy, Los Angeles, California, United States
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
- Conditions
- Colorectal Carcinoma
- First Posted Date
- 2003-01-22
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT00051987
- Locations
- 🇺🇸
Cooper Green Hospital / Jefferson Clinic P.C., Birmingham, Alabama, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Arkansas Cancer Center, Pine Bluff, Arkansas, United States
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-22
- Last Posted Date
- 2007-03-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00052000
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center @ Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2002-10-30
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 620
- Registration Number
- NCT00048230
- Locations
- 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Scripps Clinic, La Jolla, California, United States